117 related articles for article (PubMed ID: 3573809)
1. Covalent conjugates of monoclonal antibody and cobra venom factor mediate specific cytotoxicity via alternative pathway of human complement activation.
Müller B; Müller-Ruchholtz W
Leuk Res; 1987; 11(5):461-8. PubMed ID: 3573809
[TBL] [Abstract][Full Text] [Related]
2. Complement killing of human neuroblastoma cells: a cytotoxic monoclonal antibody and its F(ab')2-cobra venom factor conjugate are equally cytotoxic.
Juhl H; Petrella EC; Cheung NK; Bredehorst R; Vogel CW
Mol Immunol; 1990 Oct; 27(10):957-64. PubMed ID: 2233757
[TBL] [Abstract][Full Text] [Related]
3. Additive cytotoxicity of different monoclonal antibody-cobra venom factor conjugates for human neuroblastoma cells.
Juhl H; Petrella EC; Cheung NK; Bredehorst R; Vogel CW
Immunobiology; 1997 Nov; 197(5):444-59. PubMed ID: 9413745
[TBL] [Abstract][Full Text] [Related]
4. Induction of immune cytolysis: tumor-cell killing by complement is initiated by covalent complex of monoclonal antibody and stable C3/C5 convertase.
Vogel CW; Müller-Eberhard HJ
Proc Natl Acad Sci U S A; 1981 Dec; 78(12):7707-11. PubMed ID: 6950410
[TBL] [Abstract][Full Text] [Related]
5. Site-specific activation of the alternative pathway of complement. Synthesis of a hybrid molecule consisting of antibody and cobra venom factor.
Parker CJ; White VF; Falk RJ
Complement; 1986; 3(4):223-35. PubMed ID: 3643079
[TBL] [Abstract][Full Text] [Related]
6. The cobra complement system: I. The alternative pathway of activation.
Vogel CW; Müller-Eberhard HJ
Dev Comp Immunol; 1985; 9(2):311-25. PubMed ID: 3894085
[TBL] [Abstract][Full Text] [Related]
7. A monoclonal antibody-cobra venom factor conjugate increases the tumor-specific uptake of a 99mTc-labeled anti-carcinoembryonic antigen antibody by a two-step approach.
Juhl H; Sievers M; Baltzer K; Helmig F; Wolf H; Brenner W; Kalthoff H
Cancer Res; 1995 Dec; 55(23 Suppl):5749s-5755s. PubMed ID: 7493340
[TBL] [Abstract][Full Text] [Related]
8. Cobra venom factor immunoconjugates: effects of carbohydrate-directed versus amino group-directed conjugation.
Zara J; Pomato N; McCabe RP; Bredehorst R; Vogel CW
Bioconjug Chem; 1995; 6(4):367-72. PubMed ID: 7578355
[TBL] [Abstract][Full Text] [Related]
9. Cytolysis of Sendai virus-infected guinea-pig cells by homologous complement.
Okada H; Tanaka H; Okada N
Immunology; 1983 May; 49(1):29-35. PubMed ID: 6301976
[TBL] [Abstract][Full Text] [Related]
10. Activation of vertebrate complement by Helix pomatia haemolymph.
Koch C; Nielsen HE
Dev Comp Immunol; 1984; 8(1):15-22. PubMed ID: 6562978
[TBL] [Abstract][Full Text] [Related]
11. Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A.
Juhl H; Helmig F; Baltzer K; Kalthoff H; Henne-Bruns D; Kremer B
J Surg Oncol; 1997 Mar; 64(3):222-30. PubMed ID: 9121154
[TBL] [Abstract][Full Text] [Related]
12. Heparin and derivatized heparin inhibit zymosan and cobra venom factor activation of complement in serum.
Edens RE; Linhardt RJ; Bell CS; Weiler JM
Immunopharmacology; 1994; 27(2):145-53. PubMed ID: 8014028
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of the complement activating capacity of 17-1A mAb to overcome the effect of membrane-bound complement regulatory proteins on colorectal carcinoma.
Gelderman KA; Kuppen PJ; Bruin W; Fleuren GJ; Gorter A
Eur J Immunol; 2002 Jan; 32(1):128-35. PubMed ID: 11754353
[TBL] [Abstract][Full Text] [Related]
14. Absolute requirement for complement in monoclonal IgM antibody-mediated protection against experimental infection with type III group B streptococci.
Shigeoka AO; Jensen CL; Pincus SH; Hill HR
J Infect Dis; 1984 Jul; 150(1):63-70. PubMed ID: 6379061
[TBL] [Abstract][Full Text] [Related]
15. Study of the optimal reaction conditions for assay of the mouse alternative complement pathway.
Van Dijk H; Rademaker PM; Klerx JP; Willers JM
J Immunol Methods; 1985 Dec; 85(2):233-43. PubMed ID: 4078314
[TBL] [Abstract][Full Text] [Related]
16. Absence of a neutralizing antibody response to humanized cobra venom factor in mice.
Ing M; Hew BE; Fritzinger DC; Delignat S; Lacroix-Desmazes S; Vogel CW; Rayes J
Mol Immunol; 2018 May; 97():1-7. PubMed ID: 29525557
[TBL] [Abstract][Full Text] [Related]
17. Isolation and properties of a complement inhibitor from Naja haje venom, distinct from known anticomplementary factors in cobra venom.
von Zabern I; Przyklenk H; Damerau B; Zimmermann B
Scand J Immunol; 1981 Aug; 14(2):109-20. PubMed ID: 6914809
[TBL] [Abstract][Full Text] [Related]
18. Humanized cobra venom factor: experimental therapeutics for targeted complement activation and complement depletion.
Vogel CW; Fritzinger DC
Curr Pharm Des; 2007; 13(28):2916-26. PubMed ID: 17979736
[TBL] [Abstract][Full Text] [Related]
19. A monoclonal antibody which blocks the function of factor D of human complement.
Pascual M; Catana E; Spertini F; Macon K; Volanakis JE; Schifferli JA
J Immunol Methods; 1990 Mar; 127(2):263-9. PubMed ID: 2313104
[TBL] [Abstract][Full Text] [Related]
20. Molecular characterization of the complement activating protein in the venom of the Indian cobra (Naja N. siamensis).
Eggertsen G; Lind P; Sjöquist J
Mol Immunol; 1981 Feb; 18(2):125-33. PubMed ID: 6790937
[No Abstract] [Full Text] [Related]
[Next] [New Search]
